Unicycive Faces Legal Heat: Investors Eye Key Deadline
What Went Wrong with Unicycive? Unicycive Therapeutics, Inc., a player in the biotech space, finds itself embroiled in a legal quagmire. A class action lawsuit is hovering over NASDAQ:UNCY, spurred by allegations of the company's slip-ups in manufacturing oversight. Investors are ticked off, understandably, as the lawsuit zeroes in on failures to resolve FDA-cited issues....
Continue Reading